Jefferies Financial Group set a €75.00 ($87.21) price target on Sanofi (EPA:SAN) in a research note issued to investors on Friday. The brokerage currently has a neutral rating on the stock.

A number of other analysts have also issued reports on the company. Deutsche Bank set a €87.00 ($101.16) target price on Sanofi and gave the company a buy rating in a research report on Monday, October 1st. BNP Paribas set a €87.00 ($101.16) target price on Sanofi and gave the company a buy rating in a research report on Tuesday, September 11th. Bank of America set a €95.00 ($110.47) target price on Sanofi and gave the company a buy rating in a research report on Monday, September 10th. Citigroup set a €93.00 ($108.14) price target on shares of Sanofi and gave the stock a buy rating in a research note on Friday, August 10th. Finally, Kepler Capital Markets set a €84.00 ($97.67) price target on shares of Sanofi and gave the stock a buy rating in a research note on Monday, August 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned a buy rating to the stock. Sanofi presently has a consensus rating of Hold and a consensus price target of €79.16 ($92.04).

EPA SAN traded down €0.06 ($0.07) on Friday, reaching €66.17 ($76.94). The stock had a trading volume of 6,890,000 shares, compared to its average volume of 3,050,000. Sanofi has a 12-month low of €63.09 ($73.36) and a 12-month high of €92.97 ($108.10).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Article: Do Tariffs Work?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.